Today it was reported that the SVP, Finance and CFO of FibroGen (FGEN), Pat Controneo, exercised options to buy 7,000 FGEN shares at $2.90 a share, for a total transaction value of $20.3K.
Following this transaction Pat Controneo’s holding in the company was increased by 2.81% to a total of $11.9 million.
See today’s analyst top recommended stocks >>
Based on FibroGen’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $108 million and quarterly net profit of $20.95 million. In comparison, last year the company earned revenue of $31.93 million and had a GAAP net loss of $41.4 million. Currently, FibroGen has an average volume of 441.7K. The Company has a Price to Book ratio of 7.7865.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $71.25, reflecting a 53.5% upside. Four different firms, including Jefferies and Mizuho Securities, currently also have a Buy rating on the stock.
The insider sentiment on FibroGen has been positive according to 99 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Pat Controneo’s trades have generated a 34.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
